Biological Detection & Diagnostic Services Lead to Potential Revenue Growth as Collaborations and Innovative Product Advancements Are Announced
Jun 10, 2015, 08:40 ET
CORAL SPRINGS, Florida, June 10, 2015 /PRNewswire/ --
Technological developments, collaborations and advancements with health care services, environmental, governmental & biological detection systems race to improve services for testing, identifying and monitoring infectious risks, diseases and biohazard threats for the medical & defense industries. Health Care & Diagnostic Research Companies in focus today are: PositiveID Corporation (OTC: PSID), Prima BioMed Ltd (NASDAQ: PBMD), Sequenom, Inc. (NASDAQ: SQNM), Affymetrix, Inc., (NASDAQ: AFFX) and & Agilent Technologies Inc. (NYSE:A)
PositiveID Corporation (OTCQB: PSID), a developer of biological detection and diagnostics solutions, announced today that it has entered a co-marketing agreement with DirectView Security Systems, Inc. (OTC: DIRV ("DirectView"), a provider of video surveillance systems including body worn cameras, to jointly market the companies' products to homeland security and first responders. PositiveID develops molecular diagnostic systems, including Firefly Dx, which is designed to provide real-time, accurate diagnostic results in a handheld device, thereby leading to treatment scenarios at the point of need that are not possible with existing systems, which require lab-based equipment and can take hours or even days to provide results. Firefly's applications for first responders include point-of-need, lab-quality detection of pathogenic organisms and detection of biological agents associated with weapons of mass destruction.
Read the full PSID Press Release at http://www.financialnewsmedia.com/profiles/psid.html
DirectView provides, among other products and services, body worn cameras, video storage servers, digital video recorders, and network video recorders, to address the needs of first responders. "We are excited to enter into this co-marketing agreement with DirectView to include video surveillance solutions and body worn cameras to our line of first responder products," stated William J. Caragol, Chairman and CEO of PositiveID. "Through collaborating with companies like DirectView we accomplish two important goals: adding synergistic products and leveraging the sales channels of both companies to maximize our efforts and achieve better results."
In other Healthcare services news and happenings around the sector: Prima BioMed Ltd (NASDAQ: PBMD), a leading immuno-oncology company, recently announced that it has made substantial progress with its lead product, IMP321. Prima advises that it has filed a provisional patent application over the use of IMP321 in combination with immune checkpoint inhibitors. This breakthrough science not only bodes well for future clinical work on IMP321; it also offers commercial upside given the widespread expectation that new drugs working through various immune checkpoints will become blockbusters. In addition, this work has allowed Prima to further build on the patent estate protecting IMP321, with patent exclusivity for the product now potentially running to 2035 or beyond if granted and extended.
Sequenom, Inc. (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, announced in late May that its wholly owned subsidiary, Sequenom Laboratories, will move its laboratory operations in Grand Rapids, Michigan to its facility in Raleigh Durham, North Carolina. Sequenom Laboratories' cystic fibrosis carrier screen test will now be performed at the North Carolina laboratory location. "The expansion of our North Carolina laboratory operations to include our HerediT® CF carrier screen test will enable us to continue to provide high quality and meaningful test offerings to physicians and their patients while continuing to build value for our shareholders," said William Welch, President and Chief Executive Officer of Sequenom.
Affymetrix, Inc., (NASDAQ: AFFX) announced recently that it has acquired substantially all the assets of Hercules, CA-based Eureka Genomics® Corporation for $15 million in an all cash transaction. Eureka Genomics is a developer of cost-effective, low- to mid-plex, high throughput genotyping assays that use common next-generation sequencing (NGS) platforms for signal readout. These assays enable the detection of hundreds to thousands of genetic markers which are increasingly in demand for routine crop and animal agrigenomics testing. Affymetrix will immediately launch the Eureka Genomics' technologies as Eureka Genotyping Solution and Services for use in a wide range of routine animal and plant testing applications through an early access program.
Agilent Technologies Inc. (NYSE:A) announced updates to its SurePrint gene expression microarrays for messenger RNA profiling applications for human, mouse and rat models. The updates improve coding and noncoding content, which will provide up-to-date tools for researchers to investigate expression patterns on a highly accessible platform. Agilent developed the updates to its flagship SurePrint G3 Human v3 gene expression microarray in collaboration with Ghent University for complete coverage of the LNCipedia 2.1 database to assay high-confidence, long noncoding RNA (lncRNA) transcripts.
FinancialNewsMedia.com is leading provider of third party publishing & news dissemination services. If you would like more information regarding our news coverage solutions, please visit http://www.financialnewsmedia.com for more details. Get an edge on the market with our Premium News Alerts that are FREE for a limited time at http://www.financialnewsmedia.com/. Follow us on Facebook: http://www.facebook.com/financialnewsmedia and Twitter:http://twitter.com/FNMgroup.
DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNMG has been compensated two thousand dollars for news coverage of the current press release issued by PositiveID Corporation. by the company. FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.
Company: FN Media Group, LLC
Contact email: [email protected]
U.S. Phone: +1(954)345-0611
SOURCE FN Media Group LLC
Share this article